Fennec Pharmaceuticals Inc. (FENC) 10-Year Financial Performance & Capital Metrics

FENC • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutFennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.Show more

Revenue $48M +123.7%
EBITDA $3M +127.0%
Net Income -$436K +97.3%
EPS (Diluted) -0.02 +97.3%
Gross Margin 93.3% -0.8%
EBITDA Margin 7.08% +112.1%
Operating Margin 5.4% +109.0%
Net Margin -0.92% +98.8%
ROE -
ROIC -
Debt/Equity -
Interest Coverage 0.63 +116.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 56.8% free cash flow margin
✓Efficient asset utilization: 1.1x turnover

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-21.82%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-474.92%

EPS CAGR

10Y-

5Y-

3Y-

TTM-139.5%

ROCE

10Y Avg-94.33%

5Y Avg-61.79%

3Y Avg-51.02%

Latest8.96%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	170K	0	1.47M	21.25M	47.54M
Revenue Growth %	-	-	-	-	-	-	-1%	-	13.42%	1.24%
Cost of Goods Sold+	0	0	0	0	0	0	0	82.59K	1.26M	3.18M
COGS % of Revenue	-	-	-	-	-	-	-	0.06%	0.06%	0.07%
Gross Profit+	0	0	0	0	0	170K	0	1.39M	19.99M	44.35M
Gross Margin %	-	-	-	-	-	1%	-	0.94%	0.94%	0.93%
Gross Profit Growth %	-	-	-	-	-	-	-1%	-	13.37%	1.22%
Operating Expenses+	1.89M	2.87M	6.95M	10.41M	13.31M	18.05M	17.07M	23.09M	32.76M	41.79M
OpEx % of Revenue	-	-	-	-	-	106.21%	-	15.66%	1.54%	0.88%
Selling, General & Admin	1.63M	2.4M	5.01M	5.4M	7.57M	12.95M	12.13M	19.69M	32.71M	41.48M
SG&A % of Revenue	-	-	-	-	-	76.18%	-	13.36%	1.54%	0.87%
Research & Development	256K	472K	1.94M	5.01M	5.74M	5.11M	4.94M	3.39M	56K	307K
R&D % of Revenue	-	-	-	-	-	30.03%	-	2.3%	0%	0.01%
Other Operating Expenses	0	-14K	-8K	6K	0	0	0	0	0	0
Operating Income+	-1.89M	-2.87M	-6.95M	-10.41M	-13.31M	-17.89M	-17.07M	-21.69M	-12.77M	2.57M
Operating Margin %	-	-	-	-	-	-105.21%	-	-14.72%	-0.6%	0.05%
Operating Income Growth %	0.34%	-0.52%	-1.42%	-0.5%	-0.28%	-0.34%	0.05%	-0.27%	0.41%	1.2%
EBITDA+	-3.12M	0	0	0	-13.07M	0	-17.07M	-21.69M	-12.48M	3.37M
EBITDA Margin %	-	-	-	-	-	-	-	-14.71%	-0.59%	0.07%
EBITDA Growth %	0.13%	1%	-	-	-	1%	-	-0.27%	0.42%	1.27%
D&A (Non-Cash Add-back)	-1.23M	2.87M	6.95M	10.41M	0	17.89M	0	0	287K	800K
EBIT	-606.94K	-2.76M	-7.3M	-9.38M	-13.07M	-17.89M	-17.07M	-21.69M	-12.65M	4M
Net Interest Income+	0	0	0	0	322.32K	-324K	-72K	-783K	-2.95M	-2.48M
Interest Income	3K	0	0	0	322.32K	91.59K	54K	195K	441K	1.59M
Interest Expense	0	0	0	0	0	-	126K	978K	3.39M	4.07M
Other Income/Expense	1.28M	82K	-95K	521K	239.44K	-224K	-121.92K	-1.08M	-3.27M	-2.64M
Pretax Income+	-659K	-2.79M	-7.05M	-9.89M	-13.07M	-18.11M	-17.19M	-22.77M	-16.05M	-71K
Pretax Margin %	-	-	-	-	-	-106.52%	-	-15.45%	-0.75%	-0%
Income Tax+	-3K	-8K	-47K	-348K	0	0	0	0	0	365K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	6.14%
Net Income+	-659K	-2.79M	-7.05M	-9.89M	-13.07M	-18.11M	-17.19M	-22.77M	-16.05M	-436K
Net Margin %	-	-	-	-	-	-106.52%	-	-15.45%	-0.75%	-0.01%
Net Income Growth %	0.7%	-3.23%	-1.53%	-0.4%	-0.32%	-0.39%	0.05%	-0.32%	0.3%	0.97%
Net Income (Continuing)	-606.95K	-2.76M	-7.3M	-9.38M	-13.07M	-18.11M	-17.19M	-22.77M	-16.05M	-436K
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.06	-0.22	-0.47	-0.52	-0.63	-0.76	-0.67	-0.95	-0.60	-0.02
EPS Growth %	0.72%	-2.61%	-1.14%	-0.11%	-0.21%	-0.21%	0.12%	-0.42%	0.37%	0.97%
EPS (Basic)	-0.06	-0.22	-0.47	-0.52	-0.63	-0.76	-0.67	-0.95	-0.60	-0.02
Diluted Shares Outstanding	10.83M	12.77M	15.01M	19.02M	19.9M	23.7M	26.01M	26.27M	26.57M	27.29M
Basic Shares Outstanding	10.83M	12.68M	14.99M	18.94M	19.9M	23.7M	26.01M	26.27M	26.57M	27.29M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.02M	3.97M	28.4M	22.95M	13.88M	31.42M	22.39M	26.73M	26.86M	44.12M
Cash & Short-Term Investments	942K	3.93M	28.26M	22.78M	13.65M	30.34M	21.1M	23.77M	13.27M	26.63M
Cash Only	942K	3.93M	28.26M	22.78M	13.65M	30.34M	21.1M	23.77M	13.27M	26.63M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	1.54M	8.81M	12.88M
Days Sales Outstanding	-	-	-	-	-	-	-	382.54	151.38	98.92
Inventory	0	0	0	0	0	0	0	576K	2.16M	1.06M
Days Inventory Outstanding	-	-	-	-	-	-	-	2.55K	625.05	121.51
Other Current Assets	1K	3K	13K	1K	8K	276K	253K	63K	44K	466K
Total Non-Current Assets+	0	0	0	0	262K	0	27K	211K	6K	822K
Property, Plant & Equipment	0	0	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	262K	0	27K	211K	6K	822K
Total Assets+	1.02M	3.97M	28.4M	22.95M	14.15M	31.42M	22.41M	26.94M	26.86M	44.95M
Asset Turnover	-	-	-	-	-	0.01x	-	0.05x	0.79x	1.06x
Asset Growth %	-0.57%	2.9%	6.15%	-0.19%	-0.38%	1.22%	-0.29%	0.2%	-0%	0.67%
Total Current Liabilities+	471K	402K	1.64M	1.64M	2.27M	2.35M	1.65M	4.61M	7.55M	6.92M
Accounts Payable	297K	244K	855K	1.03M	1.61M	1.57M	777K	2.39M	3.78M	3.24M
Days Payables Outstanding	-	-	-	-	-	-	-	10.56K	1.1K	371.53
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	82K	33K	167K	0	0	0	0	0	0	248K
Current Ratio	2.16x	9.88x	17.28x	14.02x	6.11x	13.39x	13.54x	5.80x	3.56x	6.38x
Quick Ratio	2.16x	9.88x	17.28x	14.02x	6.11x	13.39x	13.54x	5.67x	3.27x	6.22x
Cash Conversion Cycle	-	-	-	-	-	-	-	-7.63K	-318.86	-151.1
Total Non-Current Liabilities+	297K	244K	855K	1.03M	0	0	4.99M	24.9M	30.93M	43.9M
Long-Term Debt	0	0	0	0	0	0	4.99M	24.9M	30.93M	19.34M
Capital Lease Obligations	0	0	0	0	0	0	0	0	2K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	24.56M
Total Liabilities	471K	402K	1.64M	1.64M	2.27M	2.35M	6.64M	29.51M	38.49M	50.82M
Total Debt+	0	0	0	0	0	0	4.99M	24.9M	30.95M	19.34M
Net Debt	-942K	-3.93M	-28.26M	-22.78M	-13.65M	-30.34M	-16.11M	1.13M	17.68M	-7.29M
Debt / Equity	-	-	-	-	-	-	0.32x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	5.74x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-2.17x
Interest Coverage	-	-	-	-	-	-	-135.49x	-22.18x	-3.76x	0.63x
Total Equity+	548K	3.57M	26.76M	21.31M	11.88M	29.07M	15.77M	-2.57M	-11.62M	-5.87M
Equity Growth %	-0.11%	5.51%	6.49%	-0.2%	-0.44%	1.45%	-0.46%	-1.16%	-3.52%	0.49%
Book Value per Share	0.05	0.28	1.78	1.12	0.60	1.23	0.61	-0.10	-0.44	-0.22
Total Shareholders' Equity	548K	3.57M	26.76M	21.31M	11.88M	29.07M	15.77M	-2.57M	-11.62M	-5.87M
Common Stock	69.15M	74.52M	103.05M	106.39M	106.39M	140.73M	140.8M	142.59M	144.31M	145.61M
Retained Earnings	-111.53M	-114.32M	-121.37M	-131.26M	-144.03M	-162.14M	-179.49M	-203.2M	-219.25M	-219.68M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1.24M	1.24M	1.24M	1.24M	1.24M	1.24M	1.24M	1.24M	1.24M	1.24M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.86M	-2.12M	-3.64M	-7.83M	-9.06M	-15.6M	-14.22M	-18.06M	-17.14M	26.98M
Operating CF Margin %	-	-	-	-	-	-91.74%	-	-12.25%	-0.81%	0.57%
Operating CF Growth %	-0.1%	-0.14%	-0.71%	-1.15%	-0.16%	-0.72%	0.09%	-0.27%	0.05%	2.57%
Net Income	-659K	-2.79M	-7.05M	-9.89M	-12.78M	-18.11M	-17.35M	-23.71M	-16.05M	-436K
Depreciation & Amortization	0	0	0	0	0	0	16K	149K	287K	959K
Stock-Based Compensation	97K	615K	1.52M	1.82M	2.67M	2.79M	4.01M	4.22M	5.35M	5.06M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-1.24M	40K	875K	105K	481K	386K	-769K	1.8M	1.43M	28.73M
Working Capital Changes	-63K	10K	1.01M	132K	569K	-663K	-138K	-509K	-8.17M	-7.33M
Change in Receivables	0	0	0	0	0	0	0	-1.54M	-7.27M	-7.87M
Change in Inventory	0	0	0	0	0	0	0	-576K	-1.58M	579K
Change in Payables	-11K	-54K	611K	177K	580K	-41K	0	0	0	0
Cash from Investing+	0	0	0	0	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	497K	5.11M	27.98M	2.35M	-71K	32.29M	4.98M	20.73M	6.64M	-13.62M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	497K	108K	594K	2.35M	-71K	322K	-8K	753K	1.72M	-439K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.86M	-2.12M	-3.64M	-7.83M	-9.06M	-15.6M	-14.22M	-18.06M	-17.14M	26.98M
FCF Margin %	-	-	-	-	-	-91.74%	-	-12.25%	-0.81%	0.57%
FCF Growth %	-0.1%	-0.14%	-0.71%	-1.15%	-0.16%	-0.72%	0.09%	-0.27%	0.05%	2.57%
FCF per Share	-0.17	-0.17	-0.24	-0.41	-0.46	-0.66	-0.55	-0.69	-0.65	0.99
FCF Conversion (FCF/Net Income)	2.83x	0.76x	0.52x	0.79x	0.69x	0.86x	0.83x	0.79x	1.07x	-61.88x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-113.52%	-135.45%	-46.47%	-41.14%	-78.78%	-88.46%	-76.68%	-344.99%	-	-
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-	-	-414.73%	-
Gross Margin	-	-	-	-	-	100%	-	94.4%	94.08%	93.3%
Net Margin	-	-	-	-	-	-10652.35%	-	-1544.89%	-75.5%	-0.92%
Debt / Equity	-	-	-	-	-	-	0.32x	-	-	-
Interest Coverage	-	-	-	-	-	-	-135.49x	-22.18x	-3.76x	0.63x
FCF Conversion	2.83x	0.76x	0.52x	0.79x	0.69x	0.86x	0.83x	0.79x	1.07x	-61.88x
Revenue Growth	-	-	-	-	-	-	-100%	-	1341.62%	123.69%

Revenue by Segment

	2020
Royalty	170K
Royalty Growth	-

Frequently Asked Questions

Growth & Financials

Fennec Pharmaceuticals Inc. (FENC) reported $38.8M in revenue for fiscal year 2024.

Fennec Pharmaceuticals Inc. (FENC) grew revenue by 123.7% over the past year. This is strong growth.

Fennec Pharmaceuticals Inc. (FENC) reported a net loss of $6.9M for fiscal year 2024.

Dividend & Returns

Fennec Pharmaceuticals Inc. (FENC) had negative free cash flow of $8.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Fennec Pharmaceuticals Inc. (FENC) 10-Year Financial Performance & Capital Metrics

FENC • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $48M +123.7%
EBITDA $3M +127.0%
Net Income -$436K +97.3%
EPS (Diluted) -0.02 +97.3%
Gross Margin 93.3% -0.8%
EBITDA Margin 7.08% +112.1%
Operating Margin 5.4% +109.0%
Net Margin -0.92% +98.8%
ROE -
ROIC -
Debt/Equity -
Interest Coverage 0.63 +116.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 56.8% free cash flow margin
✓Efficient asset utilization: 1.1x turnover

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-21.82%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-474.92%

EPS CAGR

10Y-

5Y-

3Y-

TTM-139.5%

ROCE

10Y Avg-94.33%

5Y Avg-61.79%

3Y Avg-51.02%

Latest8.96%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	170K	0	1.47M	21.25M	47.54M
Revenue Growth %	-	-	-	-	-	-	-1%	-	13.42%	1.24%
Cost of Goods Sold+	0	0	0	0	0	0	0	82.59K	1.26M	3.18M
COGS % of Revenue	-	-	-	-	-	-	-	0.06%	0.06%	0.07%
Gross Profit+	0	0	0	0	0	170K	0	1.39M	19.99M	44.35M
Gross Margin %	-	-	-	-	-	1%	-	0.94%	0.94%	0.93%
Gross Profit Growth %	-	-	-	-	-	-	-1%	-	13.37%	1.22%
Operating Expenses+	1.89M	2.87M	6.95M	10.41M	13.31M	18.05M	17.07M	23.09M	32.76M	41.79M
OpEx % of Revenue	-	-	-	-	-	106.21%	-	15.66%	1.54%	0.88%
Selling, General & Admin	1.63M	2.4M	5.01M	5.4M	7.57M	12.95M	12.13M	19.69M	32.71M	41.48M
SG&A % of Revenue	-	-	-	-	-	76.18%	-	13.36%	1.54%	0.87%
Research & Development	256K	472K	1.94M	5.01M	5.74M	5.11M	4.94M	3.39M	56K	307K
R&D % of Revenue	-	-	-	-	-	30.03%	-	2.3%	0%	0.01%
Other Operating Expenses	0	-14K	-8K	6K	0	0	0	0	0	0
Operating Income+	-1.89M	-2.87M	-6.95M	-10.41M	-13.31M	-17.89M	-17.07M	-21.69M	-12.77M	2.57M
Operating Margin %	-	-	-	-	-	-105.21%	-	-14.72%	-0.6%	0.05%
Operating Income Growth %	0.34%	-0.52%	-1.42%	-0.5%	-0.28%	-0.34%	0.05%	-0.27%	0.41%	1.2%
EBITDA+	-3.12M	0	0	0	-13.07M	0	-17.07M	-21.69M	-12.48M	3.37M
EBITDA Margin %	-	-	-	-	-	-	-	-14.71%	-0.59%	0.07%
EBITDA Growth %	0.13%	1%	-	-	-	1%	-	-0.27%	0.42%	1.27%
D&A (Non-Cash Add-back)	-1.23M	2.87M	6.95M	10.41M	0	17.89M	0	0	287K	800K
EBIT	-606.94K	-2.76M	-7.3M	-9.38M	-13.07M	-17.89M	-17.07M	-21.69M	-12.65M	4M
Net Interest Income+	0	0	0	0	322.32K	-324K	-72K	-783K	-2.95M	-2.48M
Interest Income	3K	0	0	0	322.32K	91.59K	54K	195K	441K	1.59M
Interest Expense	0	0	0	0	0	-	126K	978K	3.39M	4.07M
Other Income/Expense	1.28M	82K	-95K	521K	239.44K	-224K	-121.92K	-1.08M	-3.27M	-2.64M
Pretax Income+	-659K	-2.79M	-7.05M	-9.89M	-13.07M	-18.11M	-17.19M	-22.77M	-16.05M	-71K
Pretax Margin %	-	-	-	-	-	-106.52%	-	-15.45%	-0.75%	-0%
Income Tax+	-3K	-8K	-47K	-348K	0	0	0	0	0	365K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	6.14%
Net Income+	-659K	-2.79M	-7.05M	-9.89M	-13.07M	-18.11M	-17.19M	-22.77M	-16.05M	-436K
Net Margin %	-	-	-	-	-	-106.52%	-	-15.45%	-0.75%	-0.01%
Net Income Growth %	0.7%	-3.23%	-1.53%	-0.4%	-0.32%	-0.39%	0.05%	-0.32%	0.3%	0.97%
Net Income (Continuing)	-606.95K	-2.76M	-7.3M	-9.38M	-13.07M	-18.11M	-17.19M	-22.77M	-16.05M	-436K
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.06	-0.22	-0.47	-0.52	-0.63	-0.76	-0.67	-0.95	-0.60	-0.02
EPS Growth %	0.72%	-2.61%	-1.14%	-0.11%	-0.21%	-0.21%	0.12%	-0.42%	0.37%	0.97%
EPS (Basic)	-0.06	-0.22	-0.47	-0.52	-0.63	-0.76	-0.67	-0.95	-0.60	-0.02
Diluted Shares Outstanding	10.83M	12.77M	15.01M	19.02M	19.9M	23.7M	26.01M	26.27M	26.57M	27.29M
Basic Shares Outstanding	10.83M	12.68M	14.99M	18.94M	19.9M	23.7M	26.01M	26.27M	26.57M	27.29M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.02M	3.97M	28.4M	22.95M	13.88M	31.42M	22.39M	26.73M	26.86M	44.12M
Cash & Short-Term Investments	942K	3.93M	28.26M	22.78M	13.65M	30.34M	21.1M	23.77M	13.27M	26.63M
Cash Only	942K	3.93M	28.26M	22.78M	13.65M	30.34M	21.1M	23.77M	13.27M	26.63M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	1.54M	8.81M	12.88M
Days Sales Outstanding	-	-	-	-	-	-	-	382.54	151.38	98.92
Inventory	0	0	0	0	0	0	0	576K	2.16M	1.06M
Days Inventory Outstanding	-	-	-	-	-	-	-	2.55K	625.05	121.51
Other Current Assets	1K	3K	13K	1K	8K	276K	253K	63K	44K	466K
Total Non-Current Assets+	0	0	0	0	262K	0	27K	211K	6K	822K
Property, Plant & Equipment	0	0	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	262K	0	27K	211K	6K	822K
Total Assets+	1.02M	3.97M	28.4M	22.95M	14.15M	31.42M	22.41M	26.94M	26.86M	44.95M
Asset Turnover	-	-	-	-	-	0.01x	-	0.05x	0.79x	1.06x
Asset Growth %	-0.57%	2.9%	6.15%	-0.19%	-0.38%	1.22%	-0.29%	0.2%	-0%	0.67%
Total Current Liabilities+	471K	402K	1.64M	1.64M	2.27M	2.35M	1.65M	4.61M	7.55M	6.92M
Accounts Payable	297K	244K	855K	1.03M	1.61M	1.57M	777K	2.39M	3.78M	3.24M
Days Payables Outstanding	-	-	-	-	-	-	-	10.56K	1.1K	371.53
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	82K	33K	167K	0	0	0	0	0	0	248K
Current Ratio	2.16x	9.88x	17.28x	14.02x	6.11x	13.39x	13.54x	5.80x	3.56x	6.38x
Quick Ratio	2.16x	9.88x	17.28x	14.02x	6.11x	13.39x	13.54x	5.67x	3.27x	6.22x
Cash Conversion Cycle	-	-	-	-	-	-	-	-7.63K	-318.86	-151.1
Total Non-Current Liabilities+	297K	244K	855K	1.03M	0	0	4.99M	24.9M	30.93M	43.9M
Long-Term Debt	0	0	0	0	0	0	4.99M	24.9M	30.93M	19.34M
Capital Lease Obligations	0	0	0	0	0	0	0	0	2K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	24.56M
Total Liabilities	471K	402K	1.64M	1.64M	2.27M	2.35M	6.64M	29.51M	38.49M	50.82M
Total Debt+	0	0	0	0	0	0	4.99M	24.9M	30.95M	19.34M
Net Debt	-942K	-3.93M	-28.26M	-22.78M	-13.65M	-30.34M	-16.11M	1.13M	17.68M	-7.29M
Debt / Equity	-	-	-	-	-	-	0.32x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	5.74x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-2.17x
Interest Coverage	-	-	-	-	-	-	-135.49x	-22.18x	-3.76x	0.63x
Total Equity+	548K	3.57M	26.76M	21.31M	11.88M	29.07M	15.77M	-2.57M	-11.62M	-5.87M
Equity Growth %	-0.11%	5.51%	6.49%	-0.2%	-0.44%	1.45%	-0.46%	-1.16%	-3.52%	0.49%
Book Value per Share	0.05	0.28	1.78	1.12	0.60	1.23	0.61	-0.10	-0.44	-0.22
Total Shareholders' Equity	548K	3.57M	26.76M	21.31M	11.88M	29.07M	15.77M	-2.57M	-11.62M	-5.87M
Common Stock	69.15M	74.52M	103.05M	106.39M	106.39M	140.73M	140.8M	142.59M	144.31M	145.61M
Retained Earnings	-111.53M	-114.32M	-121.37M	-131.26M	-144.03M	-162.14M	-179.49M	-203.2M	-219.25M	-219.68M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1.24M	1.24M	1.24M	1.24M	1.24M	1.24M	1.24M	1.24M	1.24M	1.24M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.86M	-2.12M	-3.64M	-7.83M	-9.06M	-15.6M	-14.22M	-18.06M	-17.14M	26.98M
Operating CF Margin %	-	-	-	-	-	-91.74%	-	-12.25%	-0.81%	0.57%
Operating CF Growth %	-0.1%	-0.14%	-0.71%	-1.15%	-0.16%	-0.72%	0.09%	-0.27%	0.05%	2.57%
Net Income	-659K	-2.79M	-7.05M	-9.89M	-12.78M	-18.11M	-17.35M	-23.71M	-16.05M	-436K
Depreciation & Amortization	0	0	0	0	0	0	16K	149K	287K	959K
Stock-Based Compensation	97K	615K	1.52M	1.82M	2.67M	2.79M	4.01M	4.22M	5.35M	5.06M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-1.24M	40K	875K	105K	481K	386K	-769K	1.8M	1.43M	28.73M
Working Capital Changes	-63K	10K	1.01M	132K	569K	-663K	-138K	-509K	-8.17M	-7.33M
Change in Receivables	0	0	0	0	0	0	0	-1.54M	-7.27M	-7.87M
Change in Inventory	0	0	0	0	0	0	0	-576K	-1.58M	579K
Change in Payables	-11K	-54K	611K	177K	580K	-41K	0	0	0	0
Cash from Investing+	0	0	0	0	0	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	497K	5.11M	27.98M	2.35M	-71K	32.29M	4.98M	20.73M	6.64M	-13.62M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	497K	108K	594K	2.35M	-71K	322K	-8K	753K	1.72M	-439K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.86M	-2.12M	-3.64M	-7.83M	-9.06M	-15.6M	-14.22M	-18.06M	-17.14M	26.98M
FCF Margin %	-	-	-	-	-	-91.74%	-	-12.25%	-0.81%	0.57%
FCF Growth %	-0.1%	-0.14%	-0.71%	-1.15%	-0.16%	-0.72%	0.09%	-0.27%	0.05%	2.57%
FCF per Share	-0.17	-0.17	-0.24	-0.41	-0.46	-0.66	-0.55	-0.69	-0.65	0.99
FCF Conversion (FCF/Net Income)	2.83x	0.76x	0.52x	0.79x	0.69x	0.86x	0.83x	0.79x	1.07x	-61.88x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-113.52%	-135.45%	-46.47%	-41.14%	-78.78%	-88.46%	-76.68%	-344.99%	-	-
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-	-	-414.73%	-
Gross Margin	-	-	-	-	-	100%	-	94.4%	94.08%	93.3%
Net Margin	-	-	-	-	-	-10652.35%	-	-1544.89%	-75.5%	-0.92%
Debt / Equity	-	-	-	-	-	-	0.32x	-	-	-
Interest Coverage	-	-	-	-	-	-	-135.49x	-22.18x	-3.76x	0.63x
FCF Conversion	2.83x	0.76x	0.52x	0.79x	0.69x	0.86x	0.83x	0.79x	1.07x	-61.88x
Revenue Growth	-	-	-	-	-	-	-100%	-	1341.62%	123.69%

Revenue by Segment

	2020
Royalty	170K
Royalty Growth	-

Frequently Asked Questions

Growth & Financials

Fennec Pharmaceuticals Inc. (FENC) reported $38.8M in revenue for fiscal year 2024.

Fennec Pharmaceuticals Inc. (FENC) grew revenue by 123.7% over the past year. This is strong growth.

Fennec Pharmaceuticals Inc. (FENC) reported a net loss of $6.9M for fiscal year 2024.

Dividend & Returns

Fennec Pharmaceuticals Inc. (FENC) had negative free cash flow of $8.0M in fiscal year 2024, likely due to heavy capital investments.